Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL)
Research facility
Location:
Amsterdam,
Netherlands (NL)
ISNI: 0000000106741393
ROR: https://ror.org/03xqtf034
Sensitivity and Specificity in Urine Bladder Cancer Markers - Is it that Simple? Comment (2022)
Roghmann F, Goebell P, Dyrskjot L, van Rhijn BWG, Kaefferlein HU, Hakenberg O, Stenzl A, et al.
Journal article, Editorial
BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors (2021)
Haanen J, Mackensen A, Koenecke C, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al.
Conference contribution
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2021)
Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, et al.
Journal article
BNT211: A PHASE I/II TRIAL TO EVALUATE SAFETY AND EFFICACY OF CLDN6 CAR-T CELLS AND VACCINE-MEDIATED IN VIVO EXPANSION IN PATIENTS WITH CLDN6-POSITIVE ADVANCED SOLID TUMORS (2021)
Mackensen A, Koenecke C, Haanen J, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al.
Conference contribution
Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451 (2021)
Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, et al.
Journal article, Erratum
Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis (2021)
Escala-Garcia M, Canisius S, Keeman R, Beesley J, Anton-Culver H, Arndt V, Augustinsson A, et al.
Journal article
An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) (2021)
Ahrens M, Escudier B, Haanen JBAG, Boleti E, Goupil GM, Grimm MO, Negrier S, et al.
Conference contribution
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment (2021)
Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, et al.
Journal article
Risk-Adjusted Cancer Screening and Prevention (RiskAP): complementing screening for early disease detection by a learning screening based on risk factor (2021)
Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, Balmaña J, et al.
Journal article, Original article
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021)
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al.
Journal article